Measuring disease-free survival and cancer relapse using medicare claims from CALGB breast cancer trial participants (companion to 9344)

Journal of the National Cancer Institute

Volumn 98, Issue 18, 2006, Pages 1335-1338

  Lamont, Elizabeth B ^a,b   Herndon II, James E ^c   Weeks, Jane C ^b,d   Henderson, I Craig ^e   Earle, Craig C ^b,d   Schilsky, Richard L ^f   Christakis, Nicholas A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ACCURACY; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRITERION RELATED VALIDITY; DISEASE FREE SURVIVAL; ELDERLY CARE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MEDICARE; PRIORITY JOURNAL; RELIABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; VALIDATION STUDY; AREA UNDER THE CURVE; BREAST TUMOR; LYMPH NODE METASTASIS; MEDICAID; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; STATISTICS; TUMOR RECURRENCE; UNITED STATES;

AGED; ALGORITHMS; AREA UNDER CURVE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MEDICAID; MEDICARE; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 33749030689     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj363     Document Type: Article

References (13)

1. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer 1994;74(Suppl):2208-14.
2. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004;291: 2720-6.
3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
4. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MY, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-9.
5. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: The case of 5FU. Med Care 2002;40:201-11.
6. Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 2005;97:1080-3.
7. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002;12:462-8.
8. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
9. Hatten J. Medicare's common denominator: The covered population. Health Care Financ Rev 1980;2:53-64.
10. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995;76:2343-50.
11. Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 2004;39(Pt 1):1733-49.
12. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40(Suppl):IV-49-54.
13. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40(Suppl):IV-43-8.